Protalix BioTherapeutics Inc. (NYSE:PLX) saw a significant decline in short interest in September. As of September 15th, there was short interest totalling 712,565 shares, a decline of 5.4% from the August 31st total of 753,510 shares. Based on an average daily trading volume, of 134,386 shares, the short-interest ratio is currently 5.3 days. Currently, 0.8% of the shares of the stock are short sold.

Shares of Protalix BioTherapeutics (NYSE:PLX) opened at 0.5799 on Friday. The firm’s 50-day moving average price is $0.61 and its 200-day moving average price is $0.73. The stock has a market capitalization of $57.85 million and a P/E ratio of 1.1460. Protalix BioTherapeutics has a 12 month low of $0.56 and a 12 month high of $1.25.

Protalix BioTherapeutics (NYSE:PLX) last released its earnings results on Monday, August 8th. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.03. The business had revenue of $1.77 million for the quarter, compared to analyst estimates of $1.34 million. During the same quarter last year, the business earned ($0.05) earnings per share. On average, equities research analysts forecast that Protalix BioTherapeutics will post ($0.41) EPS for the current year.

A number of research firms recently commented on PLX. Zacks Investment Research downgraded Protalix BioTherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 13th. Rodman & Renshaw reiterated a “buy” rating on shares of Protalix BioTherapeutics in a research report on Monday, July 11th. Finally, Jefferies Group decreased their target price on Protalix BioTherapeutics from $1.75 to $0.80 and set a “buy” rating on the stock in a research report on Tuesday, September 6th.

5 Day Chart for NYSE:PLX

Receive News & Stock Ratings for Protalix BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc. and related stocks with our FREE daily email newsletter.